A Multi-year Contract Win for ACXM - Analyst Blog
Recently, Acxiom Corporation ( ACXM ) declared the winning of a multi-year contract for providing end-to-end services. The order came from New Jersey's biggest health insurance organization, Horizon Healthcare Services, Inc.
Acxiom shall be providing a wide range of its advanced marketing and analytic services in order to develop personalized and interconnected marketing program systems for Horizon, catering to the betterment of the latter's vast health clientele. These services shall include InfoBase, Universal Patient Link ( UPL ), Acxiom Consumer Insights and proficient consultancy services for Horizon's present and potential customers.
It is the global reputation along with expertise in providing end-to-end solutions that has made the company achieve this massive contract. Management had always retained its keen interest in technological advancements and come up with innovation-centric strategies in order to better serve its customers with state-of-the-art solutions.
On Feb 16, 2012, ThinkVine added Acxiom to its Value Added Reseller ( VAR ) program. According to this agreement, Acxiom shall incorporate ThinkVine's ThinkAhead technology platform with the intent of ameliorating sales, achieving flexibility in marketing management and yielding better returns on its marketing investments. Such moves are encouraging considering the uncertainty still prevailing in the world economic scenario.
However, Acxiom should be ever vigilant on performances of its competitors in the industry. Such ominous players include Camelot Information Systems Inc. ( CIS ), Costar Group, Inc. ( CSGP ) and Computer Task Group Inc. ( CTGX ).
The company currently retains a Zacks #3 Rank, which translates into a short-term 'Hold' rating. We also maintain a long-term 'Neutral' recommendation on the stock.
ACXIOM CORP ( ACXM ): Free Stock Analysis Report
CAMELOT INF-ADS ( CIS ): Free Stock Analysis Report
COSTAR GRP INC ( CSGP ): Free Stock Analysis Report
COMP TASK (CTGX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research